



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 28, 2019

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Press Release**

Please find enclosed press release for the financial results for the quarter and financial year ended March 31, 2019.

Please take the above on record.

Thanking you,

Yours truly,

**For Pfizer Limited**

**Prajeet Nair**  
**Company Secretary**

Encl: A/a



**Press Release  
For immediate dissemination**

**Pfizer Limited revenue from operations at ₹535.7 crore for the quarter ended March 31, 2019**

Pfizer Limited announced its audited results for the year ended March 31, 2019.

**Revenues**

Revenue from operations for the quarter ended March 31, 2019 is ₹535.7 crore as compared to ₹519.9 crore in the same period last year.

Revenue from operations for the year ended March 31, 2019 is ₹2,081.5 crore as compared to ₹1,980.2 crore in the same period last year.

Sales for the quarter and year ended March 31, 2019 is reported net of GST whereas revenue for the period up to June 30, 2017 quarter were reported including excise duty.

**Profits before other income and tax**

Profit from operations (before other income and tax) for the quarter and year ended March 31, 2019 is ₹132.8 crore and ₹492.5 crore respectively.

**Profit after tax**

Net Profit after tax (including other comprehensive income) for the quarter ended March 31, 2019 is ₹108.8 crore as against ₹112.0 crore in the same period last year. Net Profit after tax (including other comprehensive income) for the year ended March 31, 2019 is ₹430.1 crore as against ₹366.9 crore in the same period last year.

**Dividend**

The Board has recommended dividend of ₹22.50 per equity share of ₹10 each (225%) for the financial year ended March 31, 2019.

For more information,

**Investors:**

**Prajeet Nair**

Pfizer Limited

Ph : +91-9619929945

Email: [prajeet.nair@pfizer.com](mailto:prajeet.nair@pfizer.com)

**Media:**

**Chikita Sobti**

Pfizer Limited

+91-9820191347

[chikita.sobti@pfizer.com](mailto:chikita.sobti@pfizer.com)

**About Pfizer Limited:**

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at [www.pfizerindia.com](http://www.pfizerindia.com)

**Disclaimer**

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.